biotecyl

Development of orphan and ultra orphan drugs to prevent, diagnose and treat rare diseases is very challenging due to its niche nature. On the other hand, rare diseases show the potential of less intense competition, faster and less expensive development, and lower marketing spend on a small, highly motivated audience.Fleming Europe invites you to 2nd Annual Orphan Drug Congress 2012. See Program.